Abstract:Background: Acute myeloid leukemia (AML) is a highly aggressive and pathogenic hematologic malignancy with consistently high mortality. Lysosomes are organelles involved in cell growth and metabolism that fuse to form specialized Auer rods in AML, and their role in AML has not been elucidated. This study aimed to identify AML subtypes centered on lysosome-related genes and to construct a prognostic model to guide individualized treatment of AML. Methods: Gene expression data and clinical data from AML patients were downloaded from two high-throughput sequencing platforms. The 191 lysosomal signature genes were obtained from the database MsigDB. Lysosomal clusters were identified by unsupervised consensus clustering. The differences in molecular expression, biological processes, and the immune microenvironment among lysosomal clusters were subsequently analyzed. Based on the molecular expression differences between lysosomal clusters, lysosomal-related genes affecting AML prognosis were screened by univariate cox regression and multivariate cox regression analyses. Algorithms for LASSO regression analyses were employed to construct prognostic models. The risk factor distribution, KM survival curve, was applied to evaluate the survival distribution of the model. Time-dependent ROC curves, nomograms and calibration curves were used to evaluate the predictive performance of the prognostic models. TIDE scores and drug sensitivity analyses were used to explore the implication of the model for AML treatment. Results: Our study identified two lysosomal clusters, cluster1 has longer survival time and stronger immune infiltration compared to cluster2. The differences in biological processes between the two lysosomal clusters are mainly manifested in the lysosomes, vesicles, immune cell function, and apoptosis. The prognostic model consisting of six prognosis-related genes was constructed. The prognostic model showed good predictive performance in all three data sets. Patients in the low-risk group survived significantly longer than those in the high-risk group and had higher immune infiltration and stronger response to immunotherapy. Patients in the high-risk group showed greater sensitivity to cytarabine, imatinib, and bortezomib, but lower sensitivity to ATRA compared to low -risk patients. Conclusion: Our prognostic model based on lysosome-related genes can effectively predict the prognosis of AML patients and provide reference evidence for individualized immunotherapy and pharmacological chemotherapy for AML.

Glutamine metabolism-related genes predict the prognostic risk of acute myeloid leukemia and stratify patients by subtype analysis

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Plasma exosome-derived microRNA-532 as a novel predictor for acute myeloid leukemia

A combined immune and exosome-related risk signature as prognostic biomakers in acute myeloid leukemia

Prediction of prognosis and immunotherapy response of amino acid metabolism genes in acute myeloid leukemia

A Distinct Glucose Metabolism Signature of Acute Myeloid Leukemia with Prognostic Value.

Prognostic implications of metabolism-related genes in acute myeloid leukemia

Identification of Potential Novel Prognosis-Related Genes Through Transcriptome Sequencing, Bioinformatics Analysis, and Clinical Validation in Acute Myeloid Leukemia

Glutamine metabolism-related genes predict prognosis and reshape tumor microenvironment immune characteristics in diffuse gliomas

Glutamine metabolism genes prognostic signature for stomach adenocarcinoma and immune infiltration: potential biomarkers for predicting overall survival

A novel risk score model of lactate metabolism for predicting outcomes and immune signatures in acute myeloid leukemia

A Novel Glutamine Metabolism-Related Gene Signature in Prognostic Prediction of Osteosarcoma

Lysosome-related genes predict acute myeloid leukemia prognosis and response to immunotherapy

NAD metabolism-related genes provide prognostic value and potential therapeutic insights for acute myeloid leukemia

A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment

Dissecting L-glutamine metabolism in acute myeloid leukemia: single-cell insights and therapeutic implications

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia

Integrated Bioinformatic Analysis of Mitochondrial Metabolism-Related Genes in Acute Myeloid Leukemia.

Novel Prognostic Genes and Subclasses of Acute Myeloid Leukemia Revealed by Survival Analysis of Gene Expression Data.

Glutamine and leukemia research: progress and clinical prospects

Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes